Determination of the muscarinic agent [(3-(3-1-butylthio)-1,2,5-thiadiazol-4-yl)-1-azabicyclo-2.2.2-oct ane], in rat, rabbit, and monkey plasma, using high-performance liquid chromatography in conjunction with tandem mass spectrometry.
A method for determining a selective muscarinic agent, LY297802 (compound I), [(3-(3-1-butylthio)-1,2,5-thiadiazol-4-yl)-1-azabicyclo-2.2.2-octa ne], indicated in the treatment of pain, in rat, rabbit, and monkey plasma is described. The analytes, including an internal standard, were extracted from plasma at basic pH with hexane. The organic fraction was evaporated to dryness and the residue reconstituted with mobile phase. The analytes were detected utilizing HPLC in conjunction with electrospray (ES) tandem mass spectrometry (MS-MS). The limit of quantitation was 0.25 ng/ml, and the response was linear to at least 100 ng/ml.
Cornpropst
J D
JD
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA.
Gillespie
T A
TA
Shipley
L A
LA
D000818:Animals; D018678:Cholinergic Agents / Q000097:blood*; D002851:Chromatography, High Pressure Liquid; D000882:Haplorhini / Q000097:blood; D013058:Mass Spectrometry; D015394:Molecular Structure; D011817:Rabbits; D051381:Rats; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013830:Thiadiazoles / Q000097:blood*
D018678:Cholinergic Agents; D013830:Thiadiazoles; C101714:LY 297802